onr:"swepub:oai:DiVA.org:uu-318840"
Search: onr:"swepub:oai:DiVA.org:uu-318840" > Current Status of R...
- 1 of 1
- Previous record
- Next record
- To hitlist
- Fani, MelpomeniDivision of Radiopharmaceutical Chemistry, University Hospital of Basel, 4031 Basel, Switzerland (author)
Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms
- Article/chapterEnglish2017
Publisher, publication year, extent ...
- 2017-03-15
- MDPI AG,2017
- electronicrdacarrier
Numbers
- LIBRIS-ID:oai:DiVA.org:uu-318840
- https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-318840URI
- https://doi.org/10.3390/ph10010030DOI
Supplementary language notes
- Language:English
- Summary in:English
Part of subdatabase
- SwePubSwePub
Classification
Notes
- Nuclear medicine plays a pivotal role in the management of patients affected by neuroendocrine neoplasms (NENs). Radiolabeled somatostatin receptor analogs are by far the most advanced radiopharmaceuticals for diagnosis and therapy (radiotheranostics) of NENs. Their clinical success emerged receptor-targeted radiolabeled peptides as an important class of radiopharmaceuticals and it paved the way for the investigation of other radioligand-receptor systems. Besides the somatostatin receptors (sstr), other receptors have also been linked to NENs and quite a number of potential radiolabeled peptides have been derived from them. The Glucagon-Like Peptide-1 Receptor (GLP-1R) is highly expressed in benign insulinomas, the Cholecystokinin 2 (CCK2)/Gastrin receptor is expressed in different NENs, in particular medullary thyroid cancer, and the Glucose-dependent Insulinotropic Polypeptide (GIP) receptor was found to be expressed in gastrointestinal and bronchial NENs, where interestingly, it is present in most of the sstr-negative and GLP-1R-negative NENs. Also in the field of sstr targeting new discoveries brought into light an alternative approach with the use of radiolabeled somatostatin receptor antagonists, instead of the clinically used agonists. The purpose of this review is to present the current status and the most innovative strategies for the diagnosis and treatment (theranostics) of neuroendocrine neoplasms using a cadre of radiolabeled regulatory peptides targeting their receptors.
Subject headings and genre
- CCK2
- GIP
- GLP-1R
- exendin-4
- gastrin
- neuroendocrine neoplasms
- radiolabeled peptides
- somatostatin receptor antagonists
- theranostics
Added entries (persons, corporate bodies, meetings, titles ...)
- Peitl, Petra KolencDepartment of Nuclear Medicine, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia (author)
- Velikyan, Irina,1966-Uppsala universitet,Radiologi,Preparativ läkemedelskemi(Swepub:uu)irinveli (author)
- Division of Radiopharmaceutical Chemistry, University Hospital of Basel, 4031 Basel, SwitzerlandDepartment of Nuclear Medicine, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia (creator_code:org_t)
Related titles
- In:Pharmaceuticals: MDPI AG10:11424-8247
Internet link
Find in a library
- Pharmaceuticals (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Fani, Melpomeni
- Peitl, Petra Kol ...
- Velikyan, Irina, ...
- Articles in the publication
- Pharmaceuticals
- By the university
- Uppsala University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
